Innovent Biologics, Inc. (1801.HK)

HKD 36.2

(-0.82%)

Total Liabilities Summary of Innovent Biologics, Inc.

Innovent Biologics, Inc.'s latest annual total liabilities in 2023 was 8.09 Billion CNY , up 18.09% from previous year.
Innovent Biologics, Inc.'s latest quarterly total liabilities in 2023 FY was 8.09 Billion CNY , up 18.09% from previous quarter.
Innovent Biologics, Inc. reported annual total liabilities of 6.85 Billion CNY in 2022, up 15.99% from previous year.
Innovent Biologics, Inc. reported annual total liabilities of 5.91 Billion CNY in 2021, up 93.55% from previous year.
Innovent Biologics, Inc. reported quarterly total liabilities of 8.09 Billion CNY for 2023 Q4, down 0.0% from previous quarter.
Innovent Biologics, Inc. reported quarterly total liabilities of 8.09 Billion CNY for 2023 FY, up 18.09% from previous quarter.

Annual Total Liabilities Chart of Innovent Biologics, Inc. (2023 - 2016)

Historical Annual Total Liabilities of Innovent Biologics, Inc. (2023 - 2016)

Year	Total Liabilities	Total Liabilities Growth
2023	8.09 Billion CNY	18.09%
2022	6.85 Billion CNY	15.99%
2021	5.91 Billion CNY	93.55%
2020	3.05 Billion CNY	23.47%
2019	2.47 Billion CNY	29.0%
2018	1.91 Billion CNY	-52.98%
2017	4.07 Billion CNY	8.09%
2016	3.77 Billion CNY	0.0%

Year	Total Liabilities	Total Liabilities Growth
2023 Q2	7.11 Billion CNY	0.0%
2023 Q4	8.09 Billion CNY	0.0%
2023 FY	8.09 Billion CNY	18.09%
2023 Q3	8.09 Billion CNY	13.86%
2023 Q1	7.11 Billion CNY	3.72%
2022 Q1	6.56 Billion CNY	11.06%
2022 FY	6.85 Billion CNY	15.99%
2022 Q3	6.85 Billion CNY	4.44%
2022 Q2	6.56 Billion CNY	0.0%
2022 Q4	6.85 Billion CNY	0.0%
2021 Q3	5.91 Billion CNY	29.93%
2021 FY	5.91 Billion CNY	93.55%
2021 Q1	4.55 Billion CNY	48.97%
2021 Q2	4.55 Billion CNY	0.0%
2021 Q4	5.91 Billion CNY	0.0%
2020 Q1	2.54 Billion CNY	3.04%
2020 Q3	3.05 Billion CNY	19.83%
2020 Q2	2.54 Billion CNY	0.0%
2020 Q4	3.05 Billion CNY	0.0%
2020 FY	3.05 Billion CNY	23.47%
2019 FY	2.47 Billion CNY	29.0%
2019 Q4	2.47 Billion CNY	0.0%
2019 Q3	2.47 Billion CNY	19.16%
2019 Q2	2.07 Billion CNY	0.0%
2019 Q1	2.07 Billion CNY	8.26%
2018 Q1	6.46 Billion CNY	58.55%
2018 Q3	1.91 Billion CNY	-70.34%
2018 FY	1.91 Billion CNY	-52.98%
2018 Q4	1.91 Billion CNY	0.0%
2018 Q2	6.46 Billion CNY	0.0%
2017 Q3	4.07 Billion CNY	0.0%
2017 Q1	- CNY	0.0%
2017 Q4	4.07 Billion CNY	0.0%
2017 FY	4.07 Billion CNY	8.09%
2016 FY	3.77 Billion CNY	0.0%

Peer Total Liabilities Comparison of Innovent Biologics, Inc.

Name	Total Liabilities	Total Liabilities Difference
Uni-Bio Science Group Limited	152.81 Million HKD	-5200.278%
CK Life Sciences Int'l., (Holdings) Inc.	7.05 Billion HKD	-14.758%